Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib)
Sana M. Al‐Khatib(Duke University), Sean D. Pokorney(Duke University), Hussein R. Al‐Khalidi(Clinical Research Institute), Kevin Haynes(Wilmington University), Crystal Garcia(Harvard University), David Martin(United States Food and Drug Administration), Jennifer C. Goldsack(AIDS Clinical Trials Group), Thomas Harkins(University of Kentucky HealthCare), Noelle M. Cocoros(Harvard University), Nancy D. Lin(Optum (United States)), Hana Lipowicz(Harvard University), Debbe McCall, Vinit Nair(University of Kentucky HealthCare), Lauren E. Parlett(Wilmington University), Cheryl N. McMahill‐Walraven(Aetna (United States)), Richard Platt(Harvard Pilgrim Health Care), Christopher B. Granger(Duke University)
Cited by 21Open Access
Abstract
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al.|New England Journal of Medicine|2009|11.2k
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger, John H. Alexander, John J.V. McMurray et al.|New England Journal of Medicine|2011|8.9k